4D MOLECULAR THERAPEUTICS IN
FDMTNASDAQ🏆 #2674 by market capEarnings Nov 11US Equity
$11.57▲ $0.10 (+0.87%)
Live1h▼ 0.5%
24h▲ 0.9%
7d▲ 12.4%
14d▲ 20.6%
30d▲ 2.4%
1y▲ 88.0%
🏦Market Cap
$605M
Small Cap
📈Revenue Growth (YoY)
+230194.6%
High Growth
📊Gross Margin
-12.4%
Thin
💵FCF Margin
-147.4%
Thin
⚖️P/S Ratio
6.8x
Fair
Otter Score
60
Fair
📊
Analyst Ratings
Price
$11.57
Total
14
Raised
0
Lowered
1
Avg PT
$33.00
H / L
$33 / $33
| Institution | Action | Rating | Date |
|---|---|---|---|
HC Wainwright & Co. | Reiterated | Buy | 2026-07-20 |
Chardan Capital | Reiterated | Buy | 2026-03-19 |
RBC Capital | Reiterated | Outperform | 2026-03-19 |
Barclays | Reiterated | Overweight | 2025-11-11 |
Roth Capital | Reiterated | Buy | 2025-08-12 |
Goldman Sachs | Reiterated | Buy | 2025-05-09 |
B of A Securities | Reiterated | Buy | 2025-03-10 |
Leerink Partners | Reiterated | Outperform | 2025-01-13 |
Morgan Stanley | Reiterated | Underweight | 2025-01-13 |
Cantor Fitzgerald | Downgraded | Overweight → Neutral | 2024-09-23 |
BMO Capital | Reiterated | Outperform | 2024-07-18 |
Jefferies | Reiterated | Buy | 2024-04-01 |
SVB Securities | Reiterated | Market Perform | 2023-04-13 |
SVB Leerink | Reiterated | Market Perform | 2023-02-06 |
One row per institution, most recent rating